{"id":"https://openalex.org/W2325759540","doi":"https://doi.org/10.2174/187152211794519458","title":"Current Technological Development of Antibody Therapeutics","display_name":"Current Technological Development of Antibody Therapeutics","publication_year":2011,"publication_date":"2011-03-01","ids":{"openalex":"https://openalex.org/W2325759540","doi":"https://doi.org/10.2174/187152211794519458","mag":"2325759540"},"language":"en","primary_location":{"id":"doi:10.2174/187152211794519458","doi":"https://doi.org/10.2174/187152211794519458","is_oa":false,"landing_page_url":"https://doi.org/10.2174/187152211794519458","pdf_url":null,"source":{"id":"https://openalex.org/S4210228866","display_name":"Immunology Endocrine & Metabolic Agents - Medicinal Chemistry","issn_l":"1871-5222","issn":["1871-5222","1875-6115"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunology\u201a Endocrine & Metabolic Agents in Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2325759540"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103637548","display_name":"Ayami Yamaguchi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ayami Yamaguchi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008926418","display_name":"Katsuaki Usami","orcid":"https://orcid.org/0000-0003-2782-3392","observed_orcids":["https://orcid.org/0000-0003-2782-3392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katsuaki Usami","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5112765505","display_name":"Kazuhiro Masuda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I205823427","display_name":"Kyowa Kirin (Japan)","ror":"https://ror.org/000wej815","country_code":"JP","type":"company","lineage":["https://openalex.org/I205823427"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Kazuhiro Masuda","raw_affiliation_strings":["Antibody Research Laboratories, Kyowa Hakko Kirin Co., Ltd, 3-6-6, Asahi-machi, Machida-shi, Tokyo, Japan.,Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Antibody Research Laboratories, Kyowa Hakko Kirin Co., Ltd, 3-6-6, Asahi-machi, Machida-shi, Tokyo, Japan.,Japan","institution_ids":["https://openalex.org/I205823427"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5112765505"],"corresponding_institution_ids":["https://openalex.org/I205823427"],"apc_list":null,"apc_paid":null,"fwci":0.1316,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.47799795,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"11","issue":"1","first_page":"21","last_page":"32"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8050000071525574},{"id":"https://openalex.org/keywords/therapeutic-antibodies","display_name":"therapeutic antibodies","score":0.8130000233650208},{"id":"https://openalex.org/keywords/fc-engineering","display_name":"Fc engineering","score":0.9449999928474426},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9369999766349792},{"id":"https://openalex.org/keywords/complement-dependent-cytotoxicity","display_name":"complement-dependent cytotoxicity","score":0.9990000128746033},{"id":"https://openalex.org/keywords/chimeric-antibodies","display_name":"chimeric antibodies","score":0.718999981880188},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hybridoma-technology","display_name":"hybridoma technology","score":0.7319999933242798},{"id":"https://openalex.org/keywords/fc-glycosylation","display_name":"Fc glycosylation","score":0.6570000052452087},{"id":"https://openalex.org/keywords/fucose","display_name":"fucose","score":0.6420000195503235},{"id":"https://openalex.org/keywords/afucosylated-antibody","display_name":"afucosylated antibody","score":0.9710000157356262},{"id":"https://openalex.org/keywords/effector-function","display_name":"effector function","score":0.6909999847412109}],"concepts":[{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.874552845954895},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.7646420001983643},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.6830828189849854},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.45801156759262085},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.4402410387992859},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.43624016642570496},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.42549145221710205},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4216839373111725},{"id":"https://openalex.org/C125823703","wikidata":"https://www.wikidata.org/wiki/Q1616930","display_name":"Fragment crystallizable region","level":3,"score":0.42111074924468994},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3839033842086792},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.08821013569831848}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2174/187152211794519458","doi":"https://doi.org/10.2174/187152211794519458","is_oa":false,"landing_page_url":"https://doi.org/10.2174/187152211794519458","pdf_url":null,"source":{"id":"https://openalex.org/S4210228866","display_name":"Immunology Endocrine & Metabolic Agents - Medicinal Chemistry","issn_l":"1871-5222","issn":["1871-5222","1875-6115"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunology\u201a Endocrine & Metabolic Agents in Medicinal Chemistry","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W101392706","https://openalex.org/W1745948841","https://openalex.org/W2097410465","https://openalex.org/W2035343873","https://openalex.org/W2892240690","https://openalex.org/W2516720118","https://openalex.org/W1985102822","https://openalex.org/W2752201538","https://openalex.org/W2165271142","https://openalex.org/W2287054967"],"abstract_inverted_index":{"Monoclonal":[0],"antibodies":[1,26,128,195],"are":[2,75,129,196],"now":[3],"major":[4,121],"therapeutic":[5,28,64,106,125,160,194],"agents":[6],"used":[7],"to":[8,23,56,81,131,154,179],"treat":[9],"many":[10,85,117],"cancers,":[11],"immunological":[12],"and":[13,39,48,72,79,145,186],"other":[14],"diseases.":[15],"Two":[16],"big":[17],"technological":[18,52],"breakthroughs":[19],"have":[20,54,95],"enabled":[21],"us":[22],"utilize":[24],"monoclonal":[25,33],"as":[27,67,108],"agents;":[29],"the":[30,40,57,77,82,88,104,124,156,162,175,187,199,206,211],"establishment":[31],"of":[32,42,60,84,91,103,111,127,134,159,174,213],"antibody":[34,189],"production":[35],"technology":[36],"using":[37,45],"hybridomas,":[38],"reduction":[41],"immunogenicity":[43],"by":[44],"chimeric,":[46],"humanized,":[47],"fully-human":[49],"antibodies.":[50,216],"These":[51],"improvements":[53],"led":[55],"successful":[58],"launch":[59],"more":[61],"than":[62],"25":[63],"antibodies,":[65,93,161],"such":[66],"rituximab,":[68],"trastuzumab,":[69],"cetuximab,":[70],"adalimumab":[71],"ustekinumab,":[73],"which":[74],"on":[76,205],"market":[78],"contribute":[80],"health":[83],"patients.":[86],"Despite":[87],"clinical":[89,113,118],"success":[90],"these":[92],"we":[94],"also":[96],"been":[97],"faced":[98],"with":[99],"demands":[100],"for":[101],"improvement":[102],"antibodys":[105],"efficacy":[107,114],"a":[109],"result":[110],"insufficient":[112],"seen":[115],"in":[116,198,210],"trials.":[119],"The":[120],"mechanisms":[122],"underlying":[123],"effects":[126],"thought":[130],"be":[132],"neutralization":[133],"antigen":[135],"function":[136],"and/or":[137],"Fc-mediated":[138,182],"functions":[139],"e.g.":[140],"antibody-dependent":[141],"cellular":[142],"cytotoxicity":[143,147],"(ADCC)":[144],"complement-dependent":[146],"(CDC).":[148],"Among":[149],"various":[150],"efforts":[151],"being":[152],"made":[153,209],"enhance":[155],"intrinsic":[157],"capacity":[158],"most":[163],"promising":[164],"is":[165],"Fc":[166,192,214],"engineering,":[167],"including":[168],"amino":[169,224],"acid":[170,225],"mutation,":[171],"or":[172],"modification":[173],"Fc-linked":[176],"oligosaccharide":[177],"structures":[178],"dramatically":[180],"improve":[181],"functions,":[183,222],"ADCC,":[184,219],"CDC":[185],"FcRnmediated":[188],"half-life.":[190],"Some":[191],"engineered":[193,215],"evaluated":[197],"clinic.":[200],"This":[201],"review":[202],"will":[203],"focus":[204],"current":[207],"progress":[208],"development":[212],"Keywords:":[217],"Antibody,":[218],"CDC,":[220],"effector":[221],"IgG,":[223],"mutants,":[226],"domain":[227,234],"exchange":[228,235],"antibody,":[229,233],"oligosaccharides,":[230],"fucose,":[231],"afucosylated":[232],"antibyody":[236]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}